Answers are grounded in this paper and cite their sources.
The prognosis of TP53 -mutated myelodysplastic syndromes (MDS) can be heterogeneous. TP53 -mutated MDS with low variant allele frequency (VAF), without complex karyotype (CK), and those with mono-allelic TP53 alterations have significantly improved outcomes 1 , 2 , 3 . TP53 mutations are diverse and distributed across the codons of the entire coding region 4 . Different types of TP53 mutations lead to distinct functional consequences (such as oncogenic gain-of-function, protein loss-of-function with dominant-negative effect etc 5 , 6 , 7 ), that likely influence disease biology and outcome, either independently or by influencing known variables such as VAF and allelic state 2 , 3 . Until now, the relationship between various TP53 mutations and genomic/phenotypic features including outcomes is not well-characterized. This knowledge is important to assess the efficacy of novel therapeutic strategies that restore TP53 function 8 .
No takes yet. Share an insight, caveat, or question.
Kanagal‐Shamanna et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: